Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer-Reference-Cited by-同舟云学术

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer

Published:2017-11-07 Issue:3 Volume:167 Page:731-740
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Rimawi Mothaffar F.^ORCID,De Angelis Carmine,Contreras Alejandro,Pareja Fresia,Geyer Felipe C.,Burke Kathleen A.,Herrera Sabrina,Wang Tao,Mayer Ingrid A.,Forero Andres,Nanda Rita,Goetz Matthew P.,Chang Jenny C.,Krop Ian E.,Wolff Antonio C.,Pavlick Anne C.,Fuqua Suzanne A. W.,Gutierrez Carolina,Hilsenbeck Susan G.,Li Marilyn M.,Weigelt Britta,Reis-Filho Jorge S.,Kent Osborne C.,Schiff Rachel

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4533-9/fulltext.html

Reference50 articles.

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

2. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC et al (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90(18):1346–1360

3. Zardavas D, Fouad TM, Piccart M (2015) Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. Breast 24(Suppl 2):S143–S148. doi: 10.1016/j.breast.2015.07.034